Formulation and Invitro evaluation of immediate release tablets containing febuxostat


  • Srikumar Billa Department of Pharmaceutics, M.L. College of Pharmacy, S. Konda-523101.
  • Saibabu Ch Head , Department of Pharmaceutics, M.L. College of Pharmacy, S. Konda-523101.
  • T.Malyadri Assistant professor, , Department of Pharmaceutics, M.L. College of Pharmacy, S. Konda-523101.



Febuxostat, CCS, Lycoat, Crospovidone


In the present research work, Febuxostat Immediate Release Tablet was prepared by direct compression method using varying concentrations of Lycoat, Crospovidone& Croscarmellose sodium as disintegrants. The formulations prepared were evaluated for precompression& post-compression parameters. From the drug excipient compatibility studies, we observe that there are no interactions between the pure drug (Febuxostat) and optimized formulation (Febuxostat+ excipients) which indicates there are no physical changes. Post compression parameters were found to be within the limits. Among the formulation prepared the tablet containing 12mg of CCS shows 98.13% of the drug release within 45 min & follows first-order kinetics.


Download data is not yet available.


Patent applications US; 2011/0311620 and EP2582812 A0; 2011.

Febuxostat for the management of hyperuricemia in people with gout, National institute for health and care excellence, NICE technology appraisal guidance 164, United Kingdom. Available from: [Last accessed on 10 Apr 2015].

CHMP assessment report for adenuric, Procedure no. EMEA/H/C/777. Doc Ref: EMEA/258531/2008. Available from: EPAR-Public_assessment_report/human/000777/ WC500021815 .pdf. [Last accessed on 10 Aug 2014].

Cristofer E, Bryan TE, Ken O, Tomoko N, Takeshi N, Emil FP. Crystal structures of bovine milk xanthine dehydrogenase A and xanthine oxidase: structure-based mechanism of conversion. Proc Natl Acad Sci USA 2000;97:10723-8.

Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricaemia. Risks and consequences in the normative aging study. Am J Med 1987;82:421–6.

Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-416.

Mazzali M, Hughes J, Kim YG, Jefferson J, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6.

Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol 2002;282:F991-7.

Gray CL, Walters-Smith NE. Febuxostat for the treatment of chronic gout. Am J Health Syst Pharm 2011;68:389-98.

Audit support for febuxostat for the management of hyperuricemia in people with gout, National institute for health and care excellence. NICE technology appraisal guidance 164, United Kingdom. Available from: [Last accessed on 10 Apr 2014].

Uloric, Takeda Pharmaceuticals America, Inc. Available from: [Last accessed on 10 Apr 2014].

Dezani AB, Pereira TM, Caffar AM, Reis JM, Serra CHR. Equilibrium solubility versus intrinsic dissolution: characterization of lamivudine, stavudine and zidovudine for BCS classification. Braz. J. Pharm. Sci. 2013; 49(4): 853-863.

Triggle, D, J. Angiotensin II Receptor Antagonism: Losartan-Sites and Mechanisms of Action. Clin Ther. 1995; 17(6):1005-1030.

Dahan A, Miller JM, Amidon GL. Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs.AAPS J. 2009; 11(4):740-746.

Rao PLKM, Venugopal V, Anil Kumar G, Rajesh B, Prasad GAL and Ravindergoud D. Quantitative Estimation Of Losartan Potassium In Pharmaceutical Dosage Forms By Uv Spectrophotometry. IJRPC 2011, 1(3)

Rao KS, Panda M, Keshar NK. Spectrophotometric methods for the simultaneous estimation of losartan potassium and hydrochlorothiazide in tablet dosage forms. Chron Young Sci 2011;2:155-60.

P.Pranavi, Md.Gulshan, M.Eswar Gupta, N.RamaRao. Formulation and evaluation of immediaterelease irbesartan pellets and tablets. IndoAmerican journal of pharmaceutical research2014, 4(3):1617-1624.13.

Dr. B.Venkateswara Reddy, K.Navaneetha,K.Venkata Ramana Reddy. Formulation andevaluation of fast dissolving tablets of losartanpotassium. Indo American journal ofpharmaceutical research. 2014, 4(5): 2573-2584.

B.Rasmitha Reddy, B.VenkateswaraReddy,K.Navaneetha. Formulation and Evaluation ofDasatinib Immediate Release Tablets. Worldjournal of Pharmacy and Pharmaceutical sciences2014, 3(3): 1113-1123.

P. Ujwala Reddy, B.VenkateswaraReddy,K.Navaneetha. Formulation and evaluation ofcandesartan immediate release tablets by usingliquisolid technique. World journal of pharmacyand pharmaceutical sciences. 2014, 3(2): 2270-2282.

G. Deepak, Raut Rahul, A. Senthil, M. Shanteshuday. Formulation and evaluation of irbesartanimmediate release tablets. International researchjournal of pharmacy. 2012, 3(4): 410-415.

Srinivas P.Preparation and in vitro Evaluation of Nizatidine immediate release tablets. International Journal of Pharm Tech Research, 3(3), 2011, 1688-1692.

Chetan NY, Sagar SD, Amit G, Ganga S. Formulation and Evaluation of Immediate Release Tablet of Paroxetine Hydrochloride. Journal of Pharmacy Research 3(8), 2010, 1736-1738.

Sahoo CK, Venkata Ramana D, Sahoo NK, Panda KC, Panigrahy UP. Formulation and Evaluation of Immediate release Tablets of Dasatinib using Croscarmelose Sodium, Research J. Pharm. and Tech. 10(3), 2017, 833-838.

Patel N, Naruka PS, Chauhan CS, Modi J. Formulation Development and Evaluation of Immediate Release Tablet of Topiramateanti Epileptic Drug. JPSBR 3(2), 2013, 58-65.

Sahoo CK, Mohanty D, Bhaskar J, Ramana DV. Formulation and Evaluation of Fast Dissolving Tablets of Carvedilol using Sodium Starch Glycolate. Int. J. Pharm. Sci. Rev. Res., 51(1), 2018, 35-40.

Ahmed JA. A Review on fast dissolving tablet dosage form. Int.J. of Pharmacy and Pharmaceutical Research. 2 (3), 2015, 1-17.

Sahoo CK, Sahoo NK,Sahu M, Moharana AK, Sarangi DK. Formulation and Evaluation of Orodispersible Tablets of Granisetron Hydrochloride Using Agar as Natural Super disintegrants. Pharm Methods 7(1), 2016, 17-22.

Srinivas P, Mahalaxmi R.Preparation and invitro evaluation of nizatidine fast dissolving tablets. Int. J. Pharmtech Res. 3 (3), 2011, 1688-1692.

Sahoo CK, Sahoo TK, Moharana AK. Designing of orodispersible tablet of diethyl carbamazine citrate for the treatment of filariasis, Inter J Appl Biol Pharm Tech. 2, 2011, 70-74.

Sahoo CK, Sahoo NK, Sahu M, Alagarsamy V, Moharana AK, , Sarangi DK, Satyanarayana K.Formulation and evaluation of orodispersible tablets of granisetron hydrochloride using platago ovate as natural superdisintigrants, Indonesian J. Pharm. 27(1), 2016, 35-43.

Tiwari AK, Shah A, Rajpoot A, Manmohan Singhal. Formulation and In-vitro Evaluation of Fast dissolving tablets of Drotaverine HCl. J. Chem. Pharm. Res. 3(4), 2011, 333-341

Rai VK, Pathak N, Bhaskar R, Nandi BC, Dey S, Tyagi LK. Optimization of fast dissolving tablet of Raloxifene hydrochloride by wet granulation method. Int J Pharm Sci and drug Res. 1(1), 2009, 51-54.

Sahoo CK, Sudhakar M, Bhanja S, Panigrahy UP, Panda KC. Development and evaluation of immediate release tablets of dasatinib using sodium starch glycolate as super disintegrants, Innoriginal International Journal of Sciences 4(1), 2017, 1-4.

Marabathuni VJ, Dinesh P, Ravikumar R, Yamini P, Kiran PS, Hussain SP, Rao CM. Chitosan based sustained release mucoadhesive buccal patches containing amlodipine besylate (AMB). Asian J Res Pharm Sci. 2017 Jun 28;7:97-104.

Marabathuni VJ, Bhavani M, Lavanya M, Padmaja K, Madhavi N, Babu P, Rao CM. Formulation and evaluation of mouth dissolving Tablets of carbamazepine. Magnesium. 2017 Sep 27;15(30):15.

Akshay N. Jadhav, Mukesh P.Ratnaparkhi, Mayur wattamwar, and Kutmalge meghshyam. “FORMULATION AND IN-VITRO EVALUATION OF PULSATILE RELEASE OF DILTIAZEM HYDROCHLORIDE”. International Journal of Pharmaceutics and Drug Analysis, Aug. 2014, pp. 612-8,


343 Views | 232 Downloads

How to Cite

Billa, S., S. Ch, and M. T. “Formulation and Invitro Evaluation of Immediate Release Tablets Containing Febuxostat”. International Journal of Pharmaceutics and Drug Analysis, vol. 9, no. 2, July 2021, pp. 93-101, doi:10.47957/ijpda.v9i2.466.



Research Articles
Share |